84results about "Fibrinogen" patented technology

The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.

A varicella-zoster virus (VZV) nanoparticle protein, and a preparation method therefor and a use thereof. The VZV protein comprises a partial or full sequence of an amino acid sequence of an extracellular region of a VZV gE glycoprotein, with W at position 200 mutation to C and L at position 245 mutation to C in the amino acid sequence of the extracellular region of the VZV gE glycoprotein. By means of the rational optimization design of the amino acid sequence of the VZV gE protein by means of protein genetic engineering, the VZV gE recombinant protein modified with amino acid mutations has increased stability and immunogenicity compared with the VZV gE protein. Moreover, by further designing the protein structure, the VZV gE protein is repeatedly displayed on the surface of ferritin nanoparticles with the desired epitopes exposed, thereby further enhancing immunogenicity.

The present disclosure relates to a stable human platelet lysate composition; preferably a stable heparin-free human platelet lysate composition; methods for obtaining said composition and uses thereof.

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

The present invention relates to mimetics of post-translationally modified naturally occurring peptides, which bind to the peptide-binding groove of human leukocyte antigen (HLA) molecules to the same extent as the naturally occurring post-translationally modified peptides, which are recognized by T cells to the same extent as the naturally occurring post-translationally modified peptides, and which have substantially the same three-dimensional structure as the post-translationally modified naturally occurring peptides. Such peptidomimetics can be used alone, conjugated to a carrier, and are particularly useful in methods for the treatment, alleviation and prevention of autoimmune diseases, as well as components of tolerogenic vaccines.

The invention provides a preparation method and application of myofibrillar protein hydrosol, and the method comprises the following steps: uniformly dispersing myofibrillar protein in water to obtain a myofibrillar protein suspension, mixing the myofibrillar protein suspension with protein glutaminase to obtain a mixed solution A, mixing the mixed solution A with a glucan aqueous solution to carry out glycosylation reaction to obtain a mixed solution B, and carrying out freeze drying to obtain the myofibrillar protein hydrosol. And cooling in an ice-water bath, and storing at 4 DEG C to obtain the myofibrillar protein hydrosol. The myofibrillar protein hydrosol is used for preparing protein beverages and nasal feeding nutrient solutions. The method for preparing the myofibrillar protein hydrosol with excellent dispersity and storage stability at lower production cost under the condition that professional large-scale instruments and equipment are not needed is used for preparing protein beverages and nasal feeding nutrient solutions.

Disclosed are compositions and methods of a microplate-based assay related to the field of thrombosis diagnosis, therapeutic screening, and drug development platforms.

This document provides methods and materials for delivering vectors (e.g., non-viral vectors or viral vectors such as adeno-associated viral (AAV) vectors) to localized areas within a mammal (e.g., a human). For example, a fibrin hydrogel including vectors (e.g., non-viral vectors or viral vectors such as AAV vectors) can be administered directly to the retina of an eye within a mammal (e.g., a human) to deliver the vectors to the retina.

This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5' UTRs, where a 5' UTR may be expressed by a gene of a plant. In some embodiments, a 5 UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.

The invention relates to a preparation method of a biomimetic material for simulating oral masticatory mucosa and a product and application thereof, the preparation method comprises the following steps: cloning a coding gene of a protein containing a VPGXG repetitive unit into an expression vector to obtain a first expression vector; cloning the coding gene of the protein containing the VPGXG repetitive unit into the expression vector, and adding cysteine to each of the two ends of the protein to obtain a second expression vector; respectively transferring the first expression vector and the second expression vector into competent cells for expression, separation and purification of proteins to obtain a first expression vector protein and a second expression vector protein; and mixing the first expression vector protein, the second expression vector protein and the multi-arm PEG-MAL solution to obtain the multi-arm PEG-MAL. The hydrogel prepared by the invention accurately simulates the characteristics of oral chewing mucosa in mechanical properties, has no cytotoxicity, can replace real oral mucosa for experiments, and can be widely applied to the experimental fields of drug release, cell culture, gas component monitoring and the like.

The invention relates to a freeze drying method of instant fibrinogen, and belongs to the technical field of blood product preparation. The method comprises the steps of plasma pre-fusion, centrifugal separation, FI extraction, FI precipitation, dissolution and filtration, polyethylene glycol purification and separation, S / D inactivation, ethanol purification and separation, glycine purification and separation, ultrafiltration dialysis, preparation, degerming and subpackaging, freeze-drying and capping and the like. Wherein the freeze-drying process comprises four stages of pre-freezing, primary sublimation, desorption drying and plug pressing, and finally dry heat inactivation treatment is carried out. According to the method, efficient extraction and purification of fibrinogen are achieved by accurately controlling the temperature, the time, the pH value and the component proportion of various solutions in each step, and the obtained product has good instant dissolving performance and can be used in the medical fields of clinical hemostasis, tissue repair and the like.

Provided is a protein having a hexamer structure in which two molecules of a heterotrimeric protein associate at the N-terminus side, wherein the heterotrimeric protein is composed of (1) a fibrinogen Aα chain deficient in fibrinopeptide A, (2) a fibrinogen Bβ chain deficient in fibrinopeptide B and losing the ability to bind to B knob, and (3) a fibrinogen γ chain losing the ability to bind to A knob. The protein of the present invention can be used as a carrier for imparting physiological activity to fibrin gel in a thrombin-independent manner.

The present invention provides a method for fractionating human plasma using, in some embodiments, the Cohn fractionation procedure. The improvement involves using bioactive enriched plasma as the starting material for the fractionation procedure.

To provide a method for accurately determining factor XIII activity values in finished products and intermediate products in which factor XIII is purified or concentrated compared to plasma, without being affected by sample composition while also improving the workability required to measure physical properties corresponding to factor XIII activity values by using the FXIII-GLDH method.SOLUTION: Provided is a method for determining an unknown factor XIII activity value contained in a test sample by comparing the physical properties of the test sample with those of a known reference sample. The physical properties correspond to the amount of change per unit time of NAD(P)H or NAD(P)H analogues consumed or NAD(P) or NAD(P) analogues produced in the FXIII-GLDH method. The reference sample and test sample contain fibrinogen at a concentration of 2.0 to 4.0 mg / mL.SELECTED DRAWING: Figure 1

The present invention discloses a method for simultaneously separating canine fibrinogen and canine prothrombin complex from canine plasma. First, rough separation and fine separation are carried out by gel column chromatography and anion column chromatography. Then, further purification is carried out by DEAE Sephadex A-50 gel adsorption. Through the combination of multiple steps of processes and their parameters, high-purity and high-yield canine fibrinogen, prothrombin and other components can be extracted from canine plasma simultaneously. The purity of both canine fibrinogen and canine prothrombin complex can reach over 95%, and the extraction rates of canine fibrinogen and canine prothrombin complex reach over 90% and over 85% respectively, greatly improving the comprehensive utilization rate of canine plasma. At the same time, by adjusting the formula and ratio of the stabilizer, the freeze-dried products of canine fibrinogen and canine prothrombin complex have good solubility, clear solutions, and short reconstitution times, which are 10-15 minutes and 5-10 minutes respectively. In summary, the method of the present invention has stable processes, high raw material utilization rate, and good product quality.

Described herein are novel methods for fractionating and isolating platelets, platelet- and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin, and methods of using the isolated platelets, platelet and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin for regenerating tissue in a subject, treating fibrinogenemia or a clotting deficiency in a subject, treating ischemia and hypoxia, treating dry-eye syndrome, an orthopedic disorder, or a dental disorder in a subject. Also described herein are growth media for culturing mammalian (e.g., human) cells.

The application discloses a human fibrinogen high-efficiency separation device and relates to the technical field of biological medicine processing. The device comprises a tank body, a stirring mechanism and a conveying mechanism. The stirring mechanism comprises a stirring shaft and a stirring paddle. The conveying mechanism comprises a fluid channel and a liquid outlet. The stirring paddle is internally provided with a mounting cavity in communication with the fluid channel and the liquid outlet. A sliding part is slidably arranged in the mounting cavity. The device further comprises a magnetic driving assembly for driving the sliding part to reciprocatingly slide in the mounting cavity so as to extrude and spray the fluid from the liquid outlet. In the application, when the stirring paddle rotates to a specific position, the sliding part extrudes the mounting cavity under the magnetic attraction force of the permanent magnet, so that the pre-cooled ethanol is rapidly sprayed from the liquid outlet. The spraying mode makes the diffusion range of the pre-cooled ethanol in the blood plasma larger and the diffusion speed faster than those of the traditional mode, thereby avoiding the instantaneous concentration of the pre-cooled ethanol in the local part being too high, effectively preventing the denaturation of the protein in the blood plasma, avoiding the local ethanol concentration being too high and preventing the protein denaturation.

The present invention relates to platelet-binding peptides and conjugates thereof, and particles comprising these and other peptides and conjugates. Additionally, compositions and methods for using these peptides and particles are provided.

To provide: a solution having at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other proteases; and a pharmaceutical formulation comprising the solution.SOLUTION: A solution comprises: (a) fibrinogen in an amount of at least 90% of the total protein; (b) a tissue plasminogen activator in an amount of less than 50 pg / mg of the total protein; and (c) plasminogen in an amount less than 10 ng / mg of the total protein. The fibrinogen retains (i) about 90% to 100% activity after the solution is stored for at least 4 weeks at a temperature of about 0°C to about 8°C, and / or (ii) about 60% to about 70% activity after the solution is stored for 5 weeks at a temperature of about 30°C.SELECTED DRAWING: None

Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.

To provide novel marker peptides for diagnosis of pancreatic cancer.SOLUTION: A method of detecting pancreatic cancer in a subject is provided, the method comprising measuring at least either of a peptide having an amino acid sequence represented by the sequence number 1 and a peptide having an amino acid sequence represented by the sequence number 2 in a biological sample of a subject.SELECTED DRAWING: Figure 1

The present invention addresses the problem of providing a disease-treating agent which exerts an excellent effect in treating diseases requiring an emergency surgery such as heart failure and which is efficacious at a certain level for a large number of patients. The present invention pertains to a kit for preparing a disease-treating agent, said kit comprising a) a fibrinogen solution, b) a thrombin solution and c) mesenchymal stem cells, in separate forms respectively. It is preferred that c) the mesenchymal stem cells are allogeneic to a subject to be treated. Also, the present invention pertains to a kit for preparing a disease-treating agent, said kit being to be used by, when in use, suspending c) the mesenchymal stem cells in either a) the fibrinogen solution or b) the thrombin solution, and then spraying the cell suspension thus obtained directly to a disease site substantially simultaneously with either b) the thrombin solution or a) the fibrinogen solution that is not used in the suspending step.

The invention relates to a method for separating and purifying fibrinogen with low impure protein, and belongs to the technical field of blood product production. The method comprises the following steps: preparing a raw material component I, dissolving and filtering an FI precipitate, dissolving with a dissolving solution A, and filtering to obtain a filtrate A; purifying and separating polyethylene glycol, adjusting the pH value of the filtrate A, adding polyethylene glycol to precipitate, dissolving the precipitate by using the dissolving solution B, and filtering; s / D inactivation: adding an S / D solution into the filtrate B for virus inactivation; ethanol purification and separation: adding ethanol to the inactivated solution to precipitate protein, dissolving the precipitate with a dissolving solution B, and filtering; purifying and separating glycine, adding glycine precipitation protein into the filtrate C, dissolving the precipitate by using the dissolving solution C, and filtering; carrying out ultrafiltration dialysis, and dialyzing and concentrating the filtrate D; preparation: diluting the stock solution to a proper concentration; the semi-finished product is subpackaged, freeze-dried and subjected to dry heat inactivation treatment. The method can effectively remove impure proteins, improve the purity of fibrinogen and ensure the product safety.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

The invention provides a purification method and application of human fibrinogen. The method comprises the following steps: S1) mixing a component I precipitate with a cryoprecipitate, and dissolving to obtain a first liquid; s2) adjusting the pH value of the first liquid to 6.0-6.5, carrying out a first reaction, and carrying out solid-liquid separation to obtain a first precipitate; s3) sequentially performing dissolution, S / D virus inactivation and two times of PEG precipitation on the first precipitate to obtain a second precipitate; and S4) dissolving the second precipitate, and carrying out ion exchange chromatography to obtain purified human fibrinogen. The method can solve the problem of lack of a method for large-scale purification of human fibrinogen in the prior art, and is suitable for the technical field of blood products.

The present invention relates to a method for producing a fibrinogen preparation from a plasma-derived fibrinogen-containing source. The method includes the steps of providing a liquid phase containing plasma fibrinogen; contacting the liquid phase with a cation exchange chromatography material under conditions conducive to binding of fibrinogen, wherein the liquid phase has a pH in the range of pH 5.6 to pH 7.0, which is close to or higher than the pI of fibrinogen; optionally washing unbound compounds from the cation exchange chromatography material; and eluting fibrinogen from the cation exchange material. The method of the present invention is also suitable for the reduction of von Willebrand factor.

The present invention is based on fibrin-derived peptides, which are therapeutic compounds for treating inflammatory complications of virally caused diseases, such as diffuse inflammation of the endothelium, also known as systemic endotheliitis or vasculitis and related disorders. The use of fibrin-derived peptides and analogs of these compounds has resulted in surprisingly effective patient recovery.

Disclosed are compositions, uses of the compositions, methods of treatment, methods of modulating enzyme activity, methods of sequestering a target molecule, methods of delivering an enzyme, and methods of prophylaxis. In particular, the present disclosure is directed to multivalent affinity molecules having an affinity moiety and a scaffold. Multiple affinity moieties share a common scaffold to increase valency and reduce entropic penalty to produce multivalent affinity molecules with stronger and / or selective inhibition of an enzyme, for example. The multivalent affinity molecules of the present disclosure are particularly suitable for prophylaxis and treating bleeding and thrombosis associated disorders in a subject in need thereof, for modulating enzyme activity, for sequestering enzymes, and for delivering enzymes.

A method for producing a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel, the method comprising:a step 1 of applying a fibrinogen solution containing at least one selected from the group consisting of cells and drugs and fibrinogen dropwise onto a surface of a substrate made of a gelatin hydrogel;a step 2 of adding thrombin to the fibrinogen solution on the surface of the substrate;a step 3 of placing a support film on and in contact with a top surface of the fibrinogen solution to which the thrombin has been added;a step 4 of forming a fibrin sheet containing the at least one selected from the group consisting of cells and drugs in a fibrin gel between the substrate and the support film by a reaction between the fibrinogen and the thrombin; anda step 5 of melting the substrate at a temperature not lower than a melting temperature of the gelatin hydrogel to separate, from the substrate, the fibrin sheet supported by the support film.